Press & News

The next generation biopharmaceuticals

Press releases 2016

2016-05-04

Affibody Announces Initial Results from a Phase I Study of ABY-035

Solna, Sweden, May 4, 2016. Affibody AB (“Affibody”) today announced that it has completed the dose-escalation part of a Phase I study of ABY-035, which is the company’s proprietary psoriasis program. Initial results confirm compound to be safe and well-tolerated across all doses in healthy volunteers.[read more]

Older press releases

2016-04-22

Sobi™ Signs Licensing Agreement with Affibody for IL-1

Solna, Sweden, April 22, 2016 – Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that it has exercised its option to sign a licensing agreement with Swedish biotech company Affibody AB (“Affibody”) for the development of novel treatments for...[read more]

2016-04-20

Kallelse till årsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma fredagen den 20 maj 2016 klockan 16.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.[read more]

2016-04-13

Affibody AB enter into an Option Agreement regarding cancer-targeting molecules

Solna, Sweden, April 13, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Feasibility Study and Product Option Agreement with an unnamed partner.[read more]

Affibodys latest Press releases

2018-05-21

Affibody Presents at Anglonordic Life Science

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information